Trial reportJournal of the American College of Cardiology2022
Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.
Trial report in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial.Diabetes, obesity & metabolism · 2026Trial
- Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial.JAMA cardiology · 2025Trial
- Article
- Differential Influences of Achieved Blood Pressure on Cardiovascular Outcomes by Left Ventricular Geometries According to Chinese Ethnicity-Specific Echocardiographic Criteria for Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- A Clinical Prediction Model for Selective NT-proBNP Testing in Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Natriuretic peptides and cardiac troponins in hypertension and heart failure: A contemporary review of the evidence.Journal of human hypertension · 2026Review
- Ambulatory blood pressure is associated with left ventricular geometry after 10 years in hypertensive patients with continuous antihypertensive treatment.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Progress in diagnosis and treatment of hypertension combined with left ventricular hypertrophy.Annals of medicine · 2024Review
- Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?Circulation · 2024Review
- Biomarkers for Heart Failure Prediction and Prevention.Journal of cardiovascular development and disease · 2023Review
- Review
- Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control.American journal of hypertension · 2023Article
- Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control- National Health and Nutrition Examination Survey, 1999-2004.medRxiv : the preprint server for health sciences · 2023Article
- Hypertensive heart disease: risk factors, complications and mechanisms.Frontiers in cardiovascular medicine · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundLeft ventricular hypertrophy (LVH) combined with elevations in cardiac biomarkers reflecting myocardial injury and neurohormonal stress (malignant LVH) is associated with a high risk for heart failure and death.
objectivesThe aim of this study was to determine the impact of intensive systolic blood pressure (SBP) control on the prevention of malignant LVH and its consequences.
methodsA total of 8,820 participants in SPRINT (Systolic Blood Pressure Intervention Trial) were classified into groups based on the presence or absence of LVH assessed by 12-lead ECG, and elevations in biomarker levels (high-sensitivity cardiac troponin T ≥14 ng/L or N-terminal pro-B-type natriuretic peptide ≥125 pg/mL) at baseline. The effects of intensive vs standard SBP lowering on rates of acute decompensated heart failure (ADHF) events and death and on the incidence and regression of malignant LVH were determined.
resultsRandomization to intensive SBP lowering led to similar relative reductions in ADHF events and death across the combined LVH/biomarker groups (P for interaction = 0.68). The absolute risk reduction over 4 years in ADHF events and death was 4.4% (95% CI: -5.2% to 13.9%) among participants with baseline malignant LVH (n = 449) and 1.2% (95% CI: 0.0%-2.5%) for those without LVH and nonelevated biomarkers (n = 4,361). Intensive SBP lowering also reduced the incidence of malignant LVH over 2 years (2.5% vs 1.1%; OR: 0.44; 95% CI: 0.30-0.63).
conclusionsIntensive SBP lowering prevented malignant LVH and may provide substantial absolute risk reduction in the composite of ADHF events and death among SPRINT participants with baseline malignant LVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.